European Companies Search Engine
EU funding (€4,093,463): Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS Hor1 Nov 2023 EU Research and Innovation programme "Horizon"
Overview
Text
Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS
The ARISTOTELES project aims to build a multinational harmonized data platform to develop and implement novel artificial intelligence (AI) approaches for management of complex diseases, where progression and manifestations of comorbidities are via multiple interacting pathways. We aim to apply our novel approach to a population of great need due to atrial fibrillation (AF), but our outputs can be extended to other complex diseases with multimorbidity. By integrating AIs into clinical practice, our platform will form a backbone for acceptable, responsible, and respectful uses of patient/participant data to develop and validate novel trustworthy AI tools for more personalized risk assessment and management. This represents a paradigm shift in AF treatment, moving from a focus on individual risk factors and selected outcomes (eg. stroke) to a holistic approach, underpinning timely diagnostic and therapeutic interventions to reduce disease progression, disability, hospitalizations and mortality, as well as improve patient adherence to lifestyle modifications, medications, and other treatment regimens. ARISTOTELES will be delivered through 8 inter-linking work-packages (WPs): WP1 is study management/coordination. WP2 provides the ethical/legal requirements for the development of a trustworthy AI. WP3 addresses stakeholder understanding of AI, needs assessment, and engagement in all the phases of the AI development. In WP4, granular data on genotype and phenotype characteristics, are harmonized from different datasets into a common platform. In WP5, AI algorithms/tools are developed and connected to an interactive output interface for patients and clinicians. In WP6, we test the AI tool developed in WP5 in a clinical trial simulation (in silico trial). In WP7 a multicenter randomized trial runs across multiple countries including both primary care and secondary care. WP7 and WP8 drive the clinical implementation and dissemination of results.
Funded Companies:
| Company name | Funding amount |
| Aimes Management Services Ltd. | ? |
| Aalborg Universitet | €920,025 |
| Fondazione Per IL TUO Cuore Onlus | €552,475 |
| Gers SAS | €225,250 |
| Iotic Solutions SL | €353,750 |
| Moverim Srl | €212,750 |
| Panepistimio Kritis | €249,625 |
| Universidad de Murcia | €287,500 |
| Universidade de Coimbra | €16,093.75 |
| Universita Degli Studi Di Modena E Reggio Emilia | €970,500 |
| Universitatea de Medicina si Farmacie Carol Davila Din Bucuresti | €86,531 |
| Universitetet I Oslo | €218,963 |
Source: https://cordis.europa.eu/project/id/101080189
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Aimes Management Services Ltd., Liverpool.
